



ARGENICA THERAPEUTICS

INVESTOR PRESENTATION ASX: AGN

GNT XM FWJX %GNT YJHM %XZR R NY
OZQ^ %7578



DISCLAIMER

This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters: *this presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.*



ARGENICA OVERVIEW

NOVEL NEUROPROTECTIVE TREATMENTS

● STROKE	PHASE 2
● SIS ¹	PHASE 2
● HIE	PRE-CLINICAL
● TBI	PRE-CLINICAL
● ALZHEIMER'S	PRE-CLINICAL
● CARDIAC ARREST	DISCOVERY

UNTAPPED COMMERCIAL OPPORTUNITY

- URGENT & UNMET CLINICAL NEED
- NO MARKETED DRUGS AVAILABLE
- PLURI-FUNCTIONAL MECHANISM
- INCREASING INTEREST FROM **BIG PHARMA**

SUCCESSFUL CLINICAL PROGRESS

- ✓ SECURED MANUFACTURING
- ✓ COMPLETED PRE-CLINICAL STUDIES
- ✓ SUCCESSFUL PHASE 1
- ✓ BUILT CLINICAL & REGULATORY TEAM

BUILDING COMPANY VALUE

90% SHARE PRICE INCREASE FROM IPO²

PROGRESSING MULTIPLE STUDIES FOR MULTIPLE INDICATIONS TO DRIVE VALUE

ENTERING PHASE 2 TRIAL TO SHOW SAFETY + EFFICACY

1. Data collected from the recent Phase 1 clinical trial could potentially be used to progress directly into surgically induced stroke (SIS) Phase 2 trials

2. Calculated based on \$0.20 IPO and the closing share price of \$0.38 @ 21st July 2023

Argenica's lead drug candidate ARG-007 is under development and subject to clinical validation



KEY COMPANY METRICS

\$9.3M
CASH @ BANK¹

+\$4M
NON-DILUTIVE GRANTS²

R&D REFUND EXPECTED
Q4 CY23

98.3M
SHARES ON ISSUE

\$36M
MARKET CAP³

FUNDED
TO COMMENCE PHASE 2

1. Cash balance as @ 30 June 2023

2. ASX Announcement titled 'Argenica Successfully Completes \$4.0M Placement' dated 2 June 2023

3. Calculated with closing price on @ 24th July 2023 being \$0.37

OUR LEAD DRUG CANDIDATE:

ARG-007

- CATIONIC POLY-ARGININE PEPTIDE
- MULTIPLE MECHANISMS OF ACTION
- GRANTED PATENTS & STRONG IP
- SIGNIFICANT PRE-CLINICAL EFFICACY
- 25+ PUBLISHED PEER REVIEWED PAPERS
- PROVEN SAFE FOR HEALTHY HUMANS
- WORLD LEADING PARTNERS








ISCHEMIC STROKE
EXAMPLE



ARG-007 REDUCES BRAIN CELL DEATH



INITIAL INFARCTION SETS OFF A CASCADE OF CELL DEATH THAT **WILL CONTINUE SPREADING FROM LOCATION**



Without protection **1.9 million brain cells** die every minute

ARG-007 slows this brain cell death

Extends treatment window & provides neuroprotection prior to hospital

Improves recovery time and quality of life


ARG-007 STOPS THE CASCADE OF CELL DEATH & PROVIDES A PROTECTION BARRIER AROUND THE INITIAL INFARCTION



R Z Q Y N U Q J
R J H M F S M R X
T K F H Y N T S
N S X Y W T P J

ARG-007 targets multiple pathways for effective stroke therapy:

- Reduces calcium influx
- Preserves mitochondrial membrane potential
- NMDA (NR2B) downregulation
- Reduces GFAP and IL-6 expression
- Reduces MMP9 levels




ANIMAL STROKE STUDIES

Date	Animal Model	Peptide(s) Analysed	MCAO Type	Induction	Dosing (nmol/kg)	Administration (post MCAO)	Assessment (post MCAO)
2016	Sprague-Dawley rat	R18; NA-1	Permanent	Surgical	100, 300, 1000	60mins	24Hrs
2016	Sprague-Dawley rat	R18; R12; R15	Permanent	Surgical	1000	30mins	24Hrs
2016	Sprague-Dawley rat	R18; NA-1	Transient (90mins)	Surgical	30, 100, 300, 1000	60mins	24Hrs
2017	Sprague-Dawley rat	R18; R12W8a	Permanent	Surgical	30	30mins	24Hrs
2017	Sprague-Dawley rat	R18 R18; NA-1 R18; NA-1	Permanent Transient (3Hrs) Transient (2Hrs)	Surgical	100 1000 100	2Hrs 2Hrs Immediate	24Hrs 24Hrs 24Hrs
2018	Wistar rat	R18; R18D	Permanent	Surgical	300	30mins	24Hrs
2019	Sprague-Dawley rat	R18; R18D; NA-1	Transient	Chemical	100, 300, 1000	60mins	56 days
2020	Male cynomolgus macaques	R18	Transient	Surgical	1000	60mins	24Hrs & 28 days
2021	Sprague-Dawley rat	R18; R18D	Permanent	Surgical	300, 1000	10mins	45-225mins

MORE EFFECTIVE THAN OUR NEAREST COMPETITOR

Percentage reduction of brain tissue death after stroke



THE IDEAL STROKE THERAPEUTIC

PREVIOUS BARRIERS FOR NEUROPROTECTIVE DRUGS

- Do not fit into current **standard of care**
- Past drugs focused on targeting **singular** mechanisms of action and used ineffective models
- Single target treatments **have not** been effective in clinical trials
- Industry is seeking drugs that target **multiple pathways** for stroke¹

WHAT SETS ARG-007 APART

- ARG-007 has **multi-functional** mechanisms of action
- Has shown **significant efficacy** in different animal models of ischaemic stroke
- **Cell penetrating peptide** can deliver therapeutic agent to the injured brain
- **Is not degraded** by current standard of care clot dissolving drugs²
- **Does not exacerbate bleeding**³

1. Recommendations from the Stroke Treatment Academic Industry Roundtable (STAIR) urged a focus on plurifunctional agents that target multiple pathways for effective stroke therapy.
2. ASX Announcement 'Study shows arg-007 does not degrade when co-administered with ischemic stroke therapeutics' 12 July 2021
3. Liddle, L. et al (2019). *PloS one*, 14(11), e0224870.



THE STROKE OPPORTUNITY

ESTIMATED **US\$183 BILLION**
TO TREAT STROKE BY 2030¹

~550-600K ADMISSIONS FOR ACUTE
ISCHEMIC STROKE IN THE **U.S. PER YEAR**²

ARG-007 PRICE PER-DOSE EXPECTED
TO BE **USD\$8k – \$10k** - SIMILAR TO tPA³

1. Gorelick PB. "The global burden of stroke: persistent and disabling". *Lancet Neurol.* 2019 May;18(5):417-418.

2. Calculation based on the CDC estimate of total US stroke incidence. A recent nationwide surveillance study estimated that there were 552k total hospital admissions for AIS in the US in 2019: Source: CDC.gov, accessed March 2022. Asalthambi, G. et al., *Prehosp Emerg Care.* 2022 May-Jun; 26(3): 326-332; 3Ziaean, B. et al., *Stroke.* 2022;53:3386-3393; 4Ramphul K et al., *Arch Med Sci Atheroscler Dis.* 2021; 6: e132-e134. 5Akbik F et al., *JAMA Neurol.* 2020 Dec 1;77(12):1486-1495.

3. Argenica expects pricing per dose of ARG-007 to be similar to current prices for paid for tPA - a drug widely used to dissolve blood clots caused by stroke. tPA currently sells for USD8k - USD\$10k per administration

Cautionary Note: Access to markets is subject to the Company being able to successfully develop and commercialise ARG-007. As with any entity seeking to enter into a global marketplace, any product developed by Argenica will have applications that are constrained by market segment, relevant regulations, industrial application, geographical barriers and intellectual property rights.



ARG-007 CLINICAL MILESTONES ACHIEVED

- ✓ ARG-007 proved **safe and well-tolerated** in healthy human **Phase 1**
- ✓ Sterile Fill & Finish **GMP manufacturing** of ARG-007 initiated
- ✓ Stroke & Emergency Medicine **experts** to run Phase 2 trial
- ✓ Phase 2 trial site **principal investigator neurologists** engaged
- ✓ Phase 2 **ethics application submitted** to St Vincent Hospital Melbourne Human Research Ethics Committee (HREC)

PHASE 2 CLINICAL TRIAL IN STROKE

OVERVIEW

- Up to 10 Australian hospitals
- Double-blinded, randomised, placebo-controlled study
- ARG-007 will be given to patients that have suffered a diagnosed acute ischemic stroke eligible for thrombectomy
- Objectives;
 1. Safety
 2. Tolerability
 3. Pharmacokinetics
 4. Preliminary Efficacy

TIMELINE¹

	Q3 CY23	Q4 CY23	Q1 CY24	Q2 CY24
Pre-IND FDA meeting	★			
Ethics approval ²	★			
Hospital site start-up		★		
Manufacturing finalised		★		
AGR-007 arrives at sites		★		
First patient dosed			★	
First independent review of patient safety data				★

1. Timeline subject to change. A detailed Phase 2 protocol and an overview of the Phase 2 timeline will be provided following HREC approval
 2. Ethics approval is not guaranteed, and will be subject to HREC review

UM F X J 7 H QNS NH F Q WNF Q J F R



Prof. Graeme Hankey
National Coordinating Principal Investigator

As a neurologist-scientist, Professor Hankey has made an outstanding lifetime contribution to stroke research, with a special interest in epidemiological studies and clinical trials of interventions for the treatment and prevention of stroke. He is internationally recognised for his achievements and has led several pivotal studies in collaboration with leading researchers worldwide. He chairs 4 DSMBs for stroke trials and is a member of a further 6 DSMBs.



A/Prof Tina Soulis
Alithia Life Sciences, Founder and Director

A/Prof Soulis has over 27 years of working in the healthcare (pharmaceuticals and devices), biotechnology, academic research, clinical research, and management sectors in senior roles including: CEO of a Neuroscience Clinical Trials Research Organization, Director of a successful ASX200 company, VP of Clinical Strategy and Development with an innovative biotechnology company and now, Founder and Director of her own clinical consultancy company.



Dr David Blacker
Chairman – CAC / Supporting Principal Investigator

Acute stroke clinician/neurologist who has previous experience initiating neuroprotection clinical stroke trials in Western Australia and being the local Principal Investigator of a number of national and international acute and secondary prevention stroke studies. Prof Blacker is the Perron Institute Medical Director and consultant neurologist and stroke physician.



Jane Taylor
Phase 2 Project Lead

Project Lead for Argenica ARG-007 Phase 2 stroke study. Experienced Clinical Trial Project Lead with proven international experience in successful end-to-end trial management. Special interest in Neurology and imaging studies. Over 20 years' experience running clinical trials in both large global clinical research organisations including ICON Clinical Research and Syneos Health, as well as in Australian based companies.

PIPELINE OF ADDITIONAL INDICATIONS




TRAUMATIC BRAIN INJURY

- Estimated **USD\$18.6bn** market size by 2031¹
- ARG-007** has shown efficacy in pre-clinical studies²
- Awarded **A\$1.2m** grant to advance pre-clinical studies³

1. Traumatic brain injuries assessment market research, 2031 – Allied Market Research

2. ASX Announcement titled 'ARG-007 protects brain cells in moderate traumatic brain injury model' 22 June 2023

3. ASX Announcement titled 'Argenica awarded \$1.2m grant for Traumatic brain injury project under the CRC-P program' dated 20 Jan 2023




ALZHEIMER'S DISEASE

- Alzheimer's therapeutics market **USD\$13bn** by 2031⁴
- Preclinical data shows **ARG-007** inhibits **amyloid beta aggregation**, a key cause of Alzheimer's⁵
- Awarded **A\$350,000** grant to advance pre-clinical studies⁶

4. Alzheimer's Therapeutics Market Global Opportunity Analysis 2021-2031 – Allied Market Research

5. Announcement titled 'Preclinical data shows arg-007 inhibits one of The main causes of alzheimer's disease' Dated 9 Feb 2023

6. ASX Announcement titled 'Non-dilutive funding received to progress Alzheimer's disease studies' dated 22 Feb 2023



HYPOXIC-ISCHAEMIC ENCEPHALOPATHY (HIE)

- HIE occurs in **1.5 to 2.5** births per 1000⁷
- Orphan drug designation / rare paediatric disease**
- Awarded **A\$2.5m** grant to advance pre-clinical studies⁹

7. Hypoxic Ischemic Encephalopathy: Pathophysiology and Experimental Treatments Kimberly A. Allen, MSN, RN and Debra H. Brandon, PhD, RN, CCNS, FAAN

8. Pre-clinical studies have shown ARG-007 provides neuroprotection in a term animal model of Perinatal Hypoxic Ischemic Encephalopathy (HIE) – ASX Announcement 29th September 2022.

9. ASX Announcement titled 'Significant non-dilutive funding to complete preclinical hypoxic ischaemic Encephalopathy studies' dated 30 March 2023



INVESTMENT HIGHLIGHTS



**EXPERIENCED
BIOTECH TEAM**



**WORKING WITH
WORLD LEADING
EXPERTS**



**PHASE 2 ETHICS
SUBMITTED**



**OPPORTUNITY
IN MULTIPLE
APPLICATIONS
& PIPELINE**



**ACCESSED
NON-DILUTIVE
FUNDING**



**TARGETING LARGE
ADDRESSABLE
MARKETS**



ARGENICA THERAPEUTICS

For further information please contact:

Dr Liz Dallimore

CEO & Managing Director

E: info@argenica.com.au